Want to see PTHS full AI Analyst Report?
PTHS Stock Chart & Stats
$26.78
$1.67(6.44%)
At close: 4:00 PM EDT
$26.78
$1.67(6.44%)
Day’s Range― - ―
52-Week Range$14.06 - $37.50
Previous Close$27.59
Volume91.43K
Average Volume (3M)45.64K
Market Cap
$60.26M
Enterprise Value$148.57M
Total Cash (Recent Filing)$24.56M
Total Debt (Recent Filing)$73.11M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 12, 2026EPS Estimate
-3.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.93
Shares Outstanding3,828,469
10 Day Avg. Volume64,877
30 Day Avg. Volume45,642
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.50
Price to Sales (P/S)3.47
P/FCF Ratio-2.57
Enterprise Value/Market Cap2.47
Enterprise Value/Revenue3.43
Enterprise Value/Gross Profit6.27
Enterprise Value/Ebitda-2.37
Forecast
1Y Price Target
$48.40Price Target Upside80.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-16.27
Revenue Forecast (FY)$62.36M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthRapid product revenue growth and sustained sales since launch indicate increasing commercial adoption of Zelsuvmi. If this trajectory continues, a larger revenue base can improve operating leverage, support investment in the portfolio, and strengthen the company’s position in dermatology.
Expanding Prescriber And Coverage BaseBroadening payer access and a growing prescriber base create durable distribution support for the lead product. Higher coverage can reduce access friction for patients, while continued prescriber additions provide a foundation for repeat demand and future product launches.
Product Launch PipelineA defined launch roadmap gives Pelthos additional opportunities to diversify revenue beyond Zelsuvmi. Leveraging the existing commercial infrastructure could improve the efficiency of future launches, expand the dermatology portfolio, and create operating leverage as products scale.
Bears Say
Persistent Losses And Cash BurnLarge recurring losses and substantial cash consumption show that the business has not reached self-funded operations. Continued burn can restrict investment flexibility and increase reliance on financing, making execution more sensitive to revenue growth and expense control.
Negative Equity And Rising DebtThe shift to negative equity alongside sharply higher debt materially weakens balance-sheet resilience. Greater leverage can constrain future capital allocation, increase dependence on external funding, and reduce the company’s ability to absorb setbacks while commercial investments continue.
Margin And Cost PressureHigher gross-to-net deductions may reduce realized revenue per unit, while elevated COGS and SG&A pressure margins during the growth phase. Unless scale offsets these costs, expanding sales may translate slowly into profitability and prolong the company’s funding needs.
Pelthos Therapeutics News
PTHS FAQ
What was Pelthos Therapeutics’s price range in the past 12 months?
Pelthos Therapeutics lowest stock price was $14.06 and its highest was $37.50 in the past 12 months.
What is Pelthos Therapeutics’s market cap?
Pelthos Therapeutics’s market cap is $60.26M.
When is Pelthos Therapeutics’s upcoming earnings report date?
Pelthos Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 13 days.
How were Pelthos Therapeutics’s earnings last quarter?
Pelthos Therapeutics released its earnings results on Aug 13, 2026. The company reported -$6.62 earnings per share for the quarter, missing the consensus estimate of -$2.819 by -$3.801.
Is Pelthos Therapeutics overvalued?
According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued.
Does Pelthos Therapeutics pay dividends?
Pelthos Therapeutics does not currently pay dividends.
What is Pelthos Therapeutics’s EPS estimate?
Pelthos Therapeutics’s EPS estimate is -3.08.
How many shares outstanding does Pelthos Therapeutics have?
Pelthos Therapeutics has 3,828,469 shares outstanding.
What happened to Pelthos Therapeutics’s price movement after its last earnings report?
Pelthos Therapeutics reported an EPS of -$6.62 in its last earnings report, missing expectations of -$2.819. Following the earnings report the stock price went up 0.138%.
Which hedge fund is a major shareholder of Pelthos Therapeutics?
Currently, no hedge funds are holding shares in PTHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pelthos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.40 (80.73% Upside)
$48.40 (80.73% Upside)
Blogger Sentiment
Bullish
PTHS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 22.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.49%
12-Months-Change
Fundamentals
Return on Equity
-218.94%
Trailing 12-Months
Asset Growth
9999.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pelthos Therapeutics
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
PTHS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive commercial momentum story: strong quarter-over-quarter prescription and revenue growth, meaningful prescriber and coverage expansion, improving adjusted EBITDA, and a clear plan to leverage commercial infrastructure for two upcoming product launches. Notable challenges include an accounting restatement (limited to fair value measurements), higher SG&A driven largely by one-time items, a COGS increase including an API write-off, a decline in working capital, and expected gross-to-net pressure. Overall, the positive operational and commercial developments and improving profitability trends outweigh the listed challenges, though certain financial and manufacturing risks merit monitoring.View all PTHS earnings summariesPTHS Stock 12 Month Forecast
Average Price Target
$48.40
▲(80.73% Upside)
Technical Analysis
Immunic
―
Fortress Biotech
―
Verrica Pharmaceuticals
―
Instil Bio
―
Tevogen Bio Holdings
―
Ownership Overview
88.77% Insiders
2.86% Mutual Funds
0.06% Other Institutional Investors
5.74% Public Companies and
Individual Investors